Kudo, Masatoshi http://orcid.org/0000-0002-4102-3474
Okusaka, Takuji
Motomura, Kenta
Ohno, Izumi
Morimoto, Manabu
Seo, Satoru
Wada, Yoshiyuki
Sato, Shinpei
Yamashita, Tatsuya
Furukawa, Masayuki
Aramaki, Takeshi
Nadano, Seijin
Ohkawa, Kazuyoshi
Fujii, Hirofumi
Kudo, Toshihiro
Furuse, Junji
Takai, Hiroki
Homma, Gosuke
Yoshikawa, Reigetsu
Zhu, Andrew X.
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 20 October 2019
Accepted: 9 January 2020
First Online: 27 February 2020
Compliance with ethical standards
:
: MK has had a consulting/advisory role with Bayer, Bristol-Myers Squibb, Eisai Co., Ltd., MSD, and Ono Pharmaceutical; has received honoraria from Bayer, EA Pharma Co., Ltd., Eisai Co., Ltd., and MSD; and has received research funding from AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Gilead Sciences, Inc., Medico’s Hirata Inc., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical, and Takeda Pharmaceutical Company Limited. TO has received research funding from Eli Lilly Japan K.K., AstraZeneca K.K., Baxter, Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Novartis Pharma K.K., and Sumitomo Dainippon Pharma Co., Ltd. KM has received honoraria from Eisai Co., Ltd. TY has received honoraria from Eli Lilly, Bayer, and Eisai Co., Ltd. HT, GH, and RY are employees of Eli Lilly Japan K.K. and own stock in Eli Lilly and Company. IO, MM, SSeo, YW, SSato, MF, TA, SN, KO, HF, TK, JF, and AXZ have no conflicts of interest to declare.